Education
About Us
Working with TipRanks
Follow Us
Galectin Therapeutics (GALT) (GALT)
:GALT
Total Valuation
Galectin Therapeutics has a market cap or net worth of $83.40M. The enterprise value is $174.28M.
Market Cap$83.40M
Enterprise Value$174.28M
Share Statistics
Galectin Therapeutics has 63,180,492 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding63,180,492
Owned by Insiders27.63%
Owned by Institutions0.02%
Financial Efficiency
Galectin Therapeutics’s return on equity (ROE) is 0.68 and return on invested capital (ROIC) is -302.88%.
Return on Equity (ROE)0.68
Return on Assets (ROA)-1.46
Return on Invested Capital (ROIC)-302.88%
Return on Capital Employed (ROCE)-3.04
Revenue Per Employee0.00
Profits Per Employee-2.74M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Galectin Therapeutics is -2.43. Galectin Therapeutics’s PEG ratio is -0.20.
PE Ratio-2.43
PS Ratio―
PB Ratio-1.66
Price to Fair Value-1.66
Price to FCF-3.03
Price to Operating Cash Flow-3.03
PEG Ratio-0.20
Income Statement
In the last 12 months, Galectin Therapeutics had revenue of 0.00 and earned -41.07M in profits. Earnings per share was -0.74.
Revenue0.00
Gross Profit-33.00K
Operating Income-38.07M
Pretax Income-41.07M
Net Income-41.07M
EBITDA-202.00K
Earnings Per Share (EPS)-0.74
Cash Flow
In the last 12 months, operating cash flow was -33.68M and capital expenditures 0.00, giving a free cash flow of -33.68M billion.
Operating Cash Flow-33.68M
Free Cash Flow-33.68M
Free Cash Flow per Share-0.53
Dividends & Yields
Galectin Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change-61.74%
50-Day Moving Average1.47
200-Day Moving Average2.03
Relative Strength Index (RSI)44.84
Average Volume (3m)258.54K
Important Dates
Galectin Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Galectin Therapeutics as a current ratio of 1.77, with Debt / Equity ratio of -113.09%
Current Ratio1.77
Quick Ratio1.77
Debt to Market Cap0.72
Net Debt to EBITDA-228.45
Interest Coverage Ratio-14.86
Taxes
In the past 12 months, Galectin Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Galectin Therapeutics EV to EBITDA ratio is -722.83, with an EV/FCF ratio of -4.43.
EV to Sales0.00
EV to EBITDA-722.83
EV to Free Cash Flow-4.43
EV to Operating Cash Flow-4.43
Balance Sheet
Galectin Therapeutics has $27.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of $77.53M billion.
Cash & Marketable Securities$27.06M
Total Debt$0.00
Net Cash$77.53M
Net Cash Per Share$1.23
Tangible Book Value Per Share-$1.00
Margins
Gross margin is 66.25%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin66.25%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Galectin Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-1.60%